Ask us a question
520 547-3440
info@c-path.org
Subscribe
Home
About
HOW WE OPERATE
Breadth of Expertise
Core Competencies
Timeline
People
FAQ
Employment
Annual Reports
10-year Anniversary
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS
BmDR
Biomarker Data Repository
MSOAC
Multiple Sclerosis Outcome Assessments Consortium
CPAD
Critical Path For Alzheimer’s Disease
PRO Consortium
Patient-Reported Outcome Consortium
CPP
Critical Path for Parkinson’s
PKDOC
Polycystic Kidney Disease Outcomes Consortium
CP-RND
Critical Path for Rare Neurodegenerative Diseases
PredicTox KE
PredicTox Knowledge Environment
CP-SCD
Critical Path for Sickle Cell Disease
PSTC
Predictive Safety Testing Consortium
CPTA
Critical Path to Therapeutics for the Ataxias
QuantMed
Quantitative Medicine Program
CDRC
CURE Drug Repurposing Collaboratory
RDCA-DAP
Rare Disease Cures Accelerator-Data and Analytics Platform
DCC
Data Collaboration Center
RD-COA Consortium
Rare Disease Clinical Outcome Assessment Consortium
D-RSC
Duchenne Regulatory Science Consortium
TB-PACTS
TB-Platform for Aggregation of Clinical TB Studies
eCOA Consortium
Electronic Clinical Outcome Assessment Consortium
TTC
Transplant Therapeutics Consortium
FA-ICD
Friedreich’s Ataxia Integrated Clinical Database
TOMI-T1D
Trial Outcome Markers Initiative in T1D Consortium
HD-RSC
Huntington’s Disease Regulatory Science Consortium
TRxA
Translational Therapeutics Accelerator
INC
International Neonatal Consortium
T1D
Type 1 Diabetes Consortium
Completed Consortia
CFAST
Coalition for Accelerating Standards & Therapies
PTC
Pediatric Trials Consortium
CPTR
Critical Path to TB Drug Regimens
C-Path in Europe
Tools & Platforms
Training
Impact
Impact Stories
Successes
Evidentiary Considerations
Critical Connections
News & Events
Events
News
Videos
Publications
Presentations
Press Releases
Make a Gift
News
Home
>
News & Events
>
Publications
>
C-Path
>
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease
86,157
Publications
February 1, 2017
PRINT
PDF
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease
Related Posts
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
x
Contact Us
Name
Email
Phone
Message
x
Contact Us
Name
Email
Phone
Message
x
